Orgel Etan, Genkinger Jeanine M, Aggarwal Divya, Sung Lillian, Nieder Michael, Ladas Elena J
Children's Center for Cancer and Blood Disease, Children's Hospital Los Angeles, Los Angeles, CA; Jonathan Jaques Children's Cancer Center, Miller Children's Hospital Long Beach, Long Beach, CA; Keck School of Medicine, University of Southern California, Los Angeles, CA;
Mailman School of Public Health, Herbert Irving Comprehensive Cancer Center.
Am J Clin Nutr. 2016 Mar;103(3):808-17. doi: 10.3945/ajcn.115.124586. Epub 2016 Feb 10.
Obesity is a worldwide epidemic in children and adolescents. Adult cohort studies have reported an association between higher body mass index (BMI) and increased leukemia-related mortality; whether a similar effect exists in childhood leukemia remains controversial.
We conducted a meta-analysis to determine whether a higher BMI at diagnosis of pediatric acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) is associated with worse event-free survival (EFS), overall survival (OS), and cumulative incidence of relapse (CIR).
We searched 4 electronic databases from inception through March 2015 without language restriction and included studies in pediatric ALL or AML (0-21 y of age) reporting BMI as a predictor of survival or relapse. Higher BMI, defined as obese (≥95%) or overweight/obese (≥85%), was compared with lower BMI [nonoverweight/obese (<85%)]. Summary risk estimates for EFS, OS, and CIR (ALL only) were calculated with random- or fixed-effects models according to tests for between-study heterogeneity.
Of 4690 reports identified, 107 full-text articles were evaluated, with 2 additional articles identified via review of citations; 11 articles were eligible for inclusion in this meta-analysis. In ALL, we observed poorer EFS in children with a higher BMI (RR: 1.35; 95% CI: 1.20, 1.51) than in those at a lower BMI. A higher BMI was associated with significantly increased mortality (RR: 1.31; 95% CI: 1.09, 1.58) and a statistically nonsignificant trend toward greater risk of relapse (RR: 1.17; 95% CI: 0.99, 1.38) compared with a lower BMI. In AML, a higher BMI was significantly associated with poorer EFS and OS (RR: 1.36; 95% CI: 1.16, 1.60 and RR: 1.56; 95% CI: 1.32, 1.86, respectively) than was a lower BMI.
Higher BMI at diagnosis is associated with poorer survival in children with pediatric ALL or AML.
肥胖在儿童和青少年中已成为全球性的流行病。成人队列研究报告称,较高的体重指数(BMI)与白血病相关死亡率增加之间存在关联;儿童白血病是否存在类似影响仍存在争议。
我们进行了一项荟萃分析,以确定小儿急性淋巴细胞白血病(ALL)或急性髓细胞白血病(AML)诊断时较高的BMI是否与较差的无事件生存期(EFS)、总生存期(OS)和复发累积发生率(CIR)相关。
我们检索了从数据库建立至2015年3月的4个电子数据库,无语言限制,纳入报道BMI作为生存或复发预测指标的小儿ALL或AML(0至21岁)研究。将较高BMI(定义为肥胖[≥95%]或超重/肥胖[≥85%])与较低BMI[非超重/肥胖(<85%)]进行比较。根据研究间异质性检验,采用随机或固定效应模型计算EFS、OS和CIR(仅ALL)的汇总风险估计值。
在检索到的4690篇报告中,评估了107篇全文文章,通过文献综述又确定了2篇文章;11篇文章符合纳入本荟萃分析的条件。在ALL中,我们观察到BMI较高的儿童的EFS(风险比:1.35;95%置信区间:1.20,1.51)比BMI较低的儿童差。与较低BMI相比,较高BMI与死亡率显著增加(风险比:1.31;95%置信区间:1.09,1.58)以及复发风险增加的统计学无显著意义趋势(风险比:1.17;95%置信区间:0.99,1.38)相关。在AML中,与较低BMI相比,较高BMI与较差的EFS和OS显著相关(风险比分别为:1.36;95%置信区间:1.16,1.60和1.56;95%置信区间:1.32,1.86)。
小儿ALL或AML患儿诊断时较高的BMI与较差的生存率相关。